GWave Overview
GWave is a noninvasive glucometer that utilizes radio frequency waves to continuously measure blood glucose levels in real time. Its sensors are developed with proprietary AI algorithms, making GWave cost efficient, compact, and capable of delivering exceptionally accurate measurements. GWave seamlessly connects to Bluetooth and smartphones, creating a painless, straightforward, and pleasant user experience. Users can track their glucose readings as frequently as needed, and the built-in automated alarm feature ensures proper notification of fluctuations in glucose levels. The company's cloud securely stores all of the users' measurement data and can deliver important information to caretakers and medical professionals. GWave's software is safe, secure, and reliable. GWave was developed by Hagar Technology.
Cumulative Funding Raised Over Time ($)
$11.7MAug 2021
$16.7MAug 2023
$21.1MJul 2021
Latest News
growth-positive
HAGAR Secures $5 Million Funding for Non-Invasive Glucose Monitoring
HAGAR, the startup behind GWave, a non-invasive continuous glucose monitoring system, has secured a $5 million Series C funding round, bringing its total funding to $25 million. The startup showcased its latest clinical findings at the American Diabetes Association (ADA) conference. GWave offers real-time, precise blood glucose monitoring and features seamless Bluetooth and smartphone integration. The recent study demonstrated GWaves accuracy, especially during a glucose challenge. HAGAR plans to conduct more studies in the US and Israel and aims to incorporate the technology into smartwatches. The funding round was led by Columbia Pacific.
Investment
HAGAR Unveils New Clinical Data on Groundbreaking GWave Technology, Closing Round C Funding
growth-positive
Hagar showcases favorable GWave non-invasive blood glucose monitor data at ATTD following FDA breakthrough device designation
Israeli company HAGAR has showcased the encouraging study results of its GWave non-invasive blood glucose monitor at the Advanced Technologies and Treatments for Diabetes event. The glucometer, which utilizes radio frequency waves, demonstrated high accuracy and outperformed traditional finger-stick methods and continuous glucose monitors. The device has received a breakthrough device designation from the FDA and has attracted significant funding. HAGAR plans to conduct two more clinical studies later in the year. The second-generation GWave sensor is being designed to integrate with a smartwatch.
InvestmentCustomers
GWave by HAGAR to Present at Renowned Global Diabetes Conference
HAGAR GWave Awarded FDA Breakthrough Device Designation
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $21.1M |
| Last funding | $5M |
| Stage | C |
| Rounds | 3 |
| Investors | 2 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | www.hagartech.com/ |
Locations
Haifa, Israel
Photos & Videos
No files yet
GWave Business
Business models
B2B2C
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsDigital HealthcareDigital TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
SensingCommunicationsRadio FrequencyBluetoothArtificial IntelligencePlatforms & InterfacesSoftwareMobileData StorageCloudTags (14)
digital-healthcaremedical-devicesnon-invasivedigital-therapeuticsalgorithmsrf-technologyartificial-intelligencealert-systemreal-timemonitoringcloud-basedmobile-applicationsdiabetessensorsGWave Financials
$21.1M
Total funding
Undisclosed
Capital raised
$5M
Last funding
C
Funding stage
3
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$11.7MAug 2021
$16.7MAug 2023
$21.1MJul 2021
Private Equity Funding
C Round
Aug 2023
$5M
Undisclosed Investor(s)
B Round
Aug 2021
$11.7M
Columbia Pacific Capital Partners (Lead)
A Round
Jul 2021
$4.4M
Columbia Pacific Capital Partners (Lead)
GWave Lifecycle
Cumulative Funding Raised Over Time
$11.7MAug 2021
$16.7MAug 2023
$21.1MJul 2021
All Events
C Round
Aug 2023
$5M
Undisclosed Investor(s)
B Round
Aug 2021
$11.7M
Columbia Pacific Capital Partners (Lead)
A Round
Jul 2021
$4.4M
Columbia Pacific Capital Partners (Lead)
GWave News
7 articles
growth-positive
HAGAR Secures $5 Million Funding for Non-Invasive Glucose Monitoring
HAGAR, the startup behind GWave, a non-invasive continuous glucose monitoring system, has secured a $5 million Series C funding round, bringing its total funding to $25 million. The startup showcased its latest clinical findings at the American Diabetes Association (ADA) conference. GWave offers real-time, precise blood glucose monitoring and features seamless Bluetooth and smartphone integration. The recent study demonstrated GWaves accuracy, especially during a glucose challenge. HAGAR plans to conduct more studies in the US and Israel and aims to incorporate the technology into smartwatches. The funding round was led by Columbia Pacific.
Investment
HAGAR Unveils New Clinical Data on Groundbreaking GWave Technology, Closing Round C Funding
growth-positive
Hagar showcases favorable GWave non-invasive blood glucose monitor data at ATTD following FDA breakthrough device designation
Israeli company HAGAR has showcased the encouraging study results of its GWave non-invasive blood glucose monitor at the Advanced Technologies and Treatments for Diabetes event. The glucometer, which utilizes radio frequency waves, demonstrated high accuracy and outperformed traditional finger-stick methods and continuous glucose monitors. The device has received a breakthrough device designation from the FDA and has attracted significant funding. HAGAR plans to conduct two more clinical studies later in the year. The second-generation GWave sensor is being designed to integrate with a smartwatch.
InvestmentCustomers
GWave by HAGAR to Present at Renowned Global Diabetes Conference
HAGAR GWave Awarded FDA Breakthrough Device Designation
growth-positive
Hagar Raises $11.7M in Series B Funding - FinSMEs
Hagar, a developer of non-invasive continuous glucose monitoring technology, has raised $11.7 million in Series B funding. This brings their total funding to $17.1 million. The funding will be used for upcoming trials for FDA approval and completing international patents. Hagars technology, called GWave, uses RF waves to measure glucose levels in the blood continuously. The company is led by General Guy Zur and Br. General Bentzi Gruber. The technology was conceived by Dr. Gerry Waintraub.
Investment
Wave of the Future: New Glucose Technology Could Revolutionize Care
GWave Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 19 classification IDs that could be used for matching.
GWave Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 88/100 |
| Missing | video or image, markets, external profiles, not claimed |
| BI Verification | Yotam Maman |
| Crunchbase | gwave-bb3e |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-08-15T00:00:00.000Z |
| Created | 2021-08-15T00:00:00.000Z |